AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00966056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
Study NCT00966056 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teflon nasal septal splint
Description: Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
Study NCT04004169 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation-ON
Description: Active neurostimulation from the NeuroPace RNS® System triggered by a biomarker
Study NCT04004169 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Stimulation-OFF
Description: No neurostimulation from the NeuroPace RNS® System
Study NCT04004169 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation-ON Active Control
Description: Active neurostimulation from the NeuroPace RNS® System triggered by a sham biomarker
Study NCT02569944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder stimulation
Description: Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients.
Study NCT02569944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perineal bag
Description: Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
Study NCT02595593 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rib Fixation System
Description: This intervention involves a surgical procedure to affix rib plates to broken ribs
Study NCT03078699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
Study NCT03736434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness and DASH Diet Education
Description: Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines.
Study NCT03736434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and DASH Diet Education
Description: Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines.
Study NCT03736434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education group
Description: The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
Study NCT03736434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education group
Description: The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
Study NCT04693468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study NCT04693468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study NCT04693468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Isethionate
Description: Given PO
Study NCT04693468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study NCT04025073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension
Description: The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
Study NCT04025073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Description: The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
Study NCT00863096 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gardasil
Description: HPV vaccine
Study NCT01325168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: syntocinon nasal spray
Description: nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study NCT01325168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: syntocinon nasal spray
Description: nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study NCT01325168 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo nasal spray
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study NCT01325168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo nasal spray
Description: nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
Study NCT03823261 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
Study NCT01270022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation
Study NCT01270022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dissemination
Study NCT03449056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: T2 - T1+1h30: High-nasal flow and salbutamol nebulization
Study NCT01535248 — intervention group
Intervention type: OTHER
Intervention: Transthoracic Echocardiography
Description: Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
Study NCT01080105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM Web based intervention + surveillance
Description: The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
Study NCT01080105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM web based intervention
Description: The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
Study NCT01080105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational website
Description: Participants will receive access to a static educational website for 12 weeks.
Study NCT05240339 — intervention group
Intervention type: OTHER
Intervention: Observation of minor phenomena
Description: observation twice a year over 3 years
Study NCT04582448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: A single dose of insulin icodec administered subcutaneously (s.c. - under the skin) Injection in the belly, upper arm and thigh on different occasions.
Study NCT04270669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E 0.5mg
Description: The patient received one treatment of RC28-E 0.5mg in the test group
Study NCT04270669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E 1.0mg
Description: The patient received one treatment of RC28-E 1.0mg in the test group
Study NCT04270669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intravitreal injection of RC28-E2.0mg
Description: The patient received one treatment of RC28-E 2.0mg in the test group
Study NCT01179282 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dust mite extract or placebo
Description: intervention will be to stop study drug or placebo
Study NCT01179282 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: dust mite extract or placebo
Description: intervention will be to stop study drug or placebo
Study NCT02271815 — intervention group
Intervention type: OTHER
Intervention: Oral Hygiene
Description: Oral Hygiene
Study NCT03210675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Polysomnography (PSG)
Description: PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
Study NCT02778178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine plus clonidine
Description: 20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
Study NCT02778178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL saline 0.9%, per side
Study NCT02778178 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound
Study NCT02778178 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Study NCT03935581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate
Description: Auto Focusing (AF) echo imaging
Study NCT03031899 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
Study NCT03031899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rose Bengal
Description: the lesions stained positive were subjected to biopsy
Study NCT02042989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase.
Study NCT04444011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anaprazole Sodium
Description: Anaprazole Sodium isthePPI inhibitor
Study NCT03031899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: toluidine blue
Description: the lesions stained positive were subjected to biopsy
Study NCT04444011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic
Study NCT04444011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: antibiotic
Study NCT04444011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth is to protect the gastric mucosa
Study NCT01034202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One of five dose levels administered subcutaneously (under the skin)
Study NCT01034202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
Study NCT01034202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo comparator
Study NCT01034202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC126-0083
Description: One of three dose levels administered subcutaneously (under the skin)
Study NCT01034202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norditropin® SimpleXx®
Description: One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
Study NCT03292666 — intervention group
Intervention type: DRUG
Intervention: Oral Anticoagulant
Description: Oral anticoagulants used to treat or prevent venous thromboembolism
Study NCT04381728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Womed Leaf
Description: Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.
Study NCT00729664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study NCT00729664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study NCT00729664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study NCT00729664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study NCT00729664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-PDL-1 antibody
Description: Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
Study NCT00505219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
Study NCT00505219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Only
Description: Core decompression of the femoral head to remove necrotic tissue
Study NCT00756964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasburicase
Description: Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
Study NCT00756964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
Study NCT02604043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pH monitoring
Description: After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
Study NCT02604043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accelerometer monitoring
Description: Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
Study NCT01092234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional ward
Description: provision of care in a traditional unit/ward.
Study NCT01092234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Organizational change
Description: Observational unit (new organizational unit) for organizing in-hospital care
Study NCT01571219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
Study NCT06047730 — intervention group
Intervention type: PROCEDURE
Intervention: operation ways
Description: nothing
Study NCT03919552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel,Carboplatin
Description: Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
Study NCT03919552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel,Cisplatin
Description: Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
Study NCT03919552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carboplatin-based concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
Study NCT03919552 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin-based concurrent chemoradiotherapy
Description: Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Study NCT01812109 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy
Description: Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes \~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
Study NCT03137160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Injection
Study NCT01737632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy (MDFT)
Description: MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
Study NCT01737632 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Adolescent Residential Treatment
Description: The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
Study NCT03956979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010 group A
Description: JM-010 fixed combination drug (Group A) + Placebo 2
Study NCT03956979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010 group B
Description: JM-010 fixed combination drug (Group B) + Placebo 1
Study NCT03956979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo 1 + Placebo 2
Study NCT00779935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remicade
Description: Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.